Alerta

Application of ZEB1 in analysis and treatment of Crohn disease related diseases

Resumen de: CN121700056A

The invention belongs to the technical field of biology, and relates to application of ZEB1 in analysis and treatment of Crohn disease related diseases. Specifically, the invention discloses application of a reagent for detecting the expression level of ZEB1 in preparation of a product for analyzing the severity of Crohn's disease and the risk and severity of intestinal fibrosis stenosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis. The reagent for inhibiting ZEB1 expression is applied to preparation of products for inhibiting Crohn's disease complicated with intestinal fibrosis or stenosis. The invention determines that ZEB1 can be used as a biomarker of intestinal fibrosis of Crohn's disease, the expression level of ZEB1 is associated with the risk and severity of intestinal fibrosis or intestinal fibrosis stenosis complicated by Crohn's disease, and a new method is provided for clinically evaluating the risk and severity of disease. Meanwhile, it is clear that ZEB1 can be used as a target spot for treating Crohn's disease complicated with intestinal fibrosis or intestinal fibrosis stenosis.

ANTI-TL1A ANTIBODY THERAPEUTIC METHODS

Resumen de: US20260078194A1

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

GENE-BASED DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

Resumen de: JP2026048696A

The present invention provides methods of predicting a subject's likelihood of developing Inflammatory Bowel Disease (IBD) and methods of diagnosing Inflammatory Bowel Disease (IBD) in a subject. Further provided are methods of identifying genes/loci associated with disease states such as IBD, CD, and/or UC.SOLUTION: A method of predicting a subject's likelihood of developing inflammatory bowel disease, the method comprising: Identifying a genotype of a subject for a risk allele of a gene/locus; and predicting a high likelihood of developing IBD in the subject after detection of the risk allele; or predicting a low likelihood of developing IBD in the subject if the risk allele is not detected.SELECTED DRAWING: FIG. 8C

DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS

Resumen de: WO2024227011A1

Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.

METHOD OF TREATMENT

Resumen de: WO2024227232A1

The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.

PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING VARIOUS INFLAMMATORY DISORDERS

Resumen de: JP2026041895A

Provided are methods of treating, preventing and/or delaying the progression of various chronic inflammatory disorders including: (1) type 2 diabetes; (2) acute respiratory distress syndrome; (3) chronic autoimmune inflammatory disorders; (4) inflammatory bowel disease; (5) metabolome-mediated diseases; and (6) hyperphagia disorders.SOLUTION: A method is provided comprising orally administering a pharmaceutical composition comprising a denatonium salt. Further provided is a pharmaceutical composition for the treatment and prevention of various inflammatory conditions that can be tracked by pro-inflammatory biomarkers comprising a denatonium salt that delivers a total daily dose of about 20 mg to about 5000 mg BID to an adult human. Preferably, the denatonium salt is selected from the group consisting of denatonium acetate, denatonium citrate, denatonium maleate, denatonium saccharide and denatonium tartrate.SELECTED DRAWING: None

Methods and systems for diagnosing inflammatory bowel disease (IBD)

Resumen de: CN121620703A

The present invention relates to methods and kits for diagnosing inflammatory bowel disease (IBD) in a subject. The diagnostic method is based on the detection of fecal calprotectin and at least one other fecal biomarker selected from the group consisting of PGRP-S and MMP-8 in a fecal sample from a subject. In a preferred embodiment, the obtained fecal biomarker concentration data is analyzed by supervising a machine learning diagnostic model, and classified as being affected or not affected by IBD.

AGENTS AND METHODS DIRECTED TO DISEASE-ASSOCIATED CELLS

Resumen de: WO2026047225A1

Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.

COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL TESTING OF STOOL

Resumen de: US20260060660A1

The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.

PRÜFKÖRPER SOWIE VERFAHREN, PRÜFSTAND UND VERWENDUNG EINES PRÜFKÖRPERS ZUM ERMITTELN EINER MECHANISCHEN BELASTBARKEIT EINES UMHÜLLUNGSSYSTEMS FÜR ERDVERLEGTE STAHLROHRE

Resumen de: DE102024124516A1

Ein Prüfkörper (10), ibs. zum Eindrücken in einen zu prüfenden Gegenstand (12), der bsw. ein Umhüllungssystem für erdverlegte Stahlrohre (14) ist, hat die Gestalt eines Pyramidenstumpfes, Kegelstumpfes oder einer Halbkugelschicht mit einer Grundfläche (10g) und einer Deckfläche (10d), wobei- die Projektion der Deckfläche auf die Grundfläche innerhalb der Grundfläche liegt;- die Deckfläche parallel zu der Grundfläche ist.Ein Verfahren zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst, dass- der Prüfkörper mit der Deckfläche voran von außen gegen das Umhüllungssystem gemäß einem vorbestimmten Wegverlauf und/oder Kraftverlauf gedrückt wird;- die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfasst wird;- die Belastbarkeit abhängig von der erfassten Eindringtiefe ermittelt wird.Ein Prüfstand (16) zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst- ein Haltesystem (18);- eine Materialprüfmaschine (20), die den Prüfkörper mit der Deckfläche voran gegen das Umhüllungssystem drücken kann;- eine Messeinrichtung (22), die die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfassen kann;- eine Steuereinrichtung (24), die gemäß dem Verfahren die Materialprüfmaschine und die Messeinrichtung ansteuern und die Belastbarkeit ermitteln kann.Der Prüfkörper wird zum Ermitteln der mechanischen Belastbarkeit gemäß dem Verfahre

Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Resumen de: AU2026201149A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b

METHODS FOR IDENTIFYING AND TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: WO2026050646A1

This disclosure concerns metabolites that can be used to identify and characterize inflammatory bowel disease (IBD) as well as assess treatment for IBD.

Nano-enzyme coating recombinant probiotics as well as preparation method and application thereof

Resumen de: CN121592569A

The invention discloses nano-enzyme coating recombinant probiotics as well as a preparation method and application thereof, and belongs to the technical field of biotechnology and nano medicine. According to the invention, engineered Escherichia coli Nissle 1917 (ECN (DE3)) is taken as a host, and glutathione peroxidase (GPX) and glutathione reductase (GR) genes are over-expressed through a genetic engineering means, so that an efficient antioxidant enzyme system is constructed. And sequentially modifying chitosan and cerium dioxide nano-enzyme (CNP) on the surfaces of the thalli by using an electrostatic layer-by-layer self-assembly technology to form a protective coating. The nano-enzyme coating significantly improves the survival rate of the recombinant probiotics in severe environments such as simulated gastric acid (pH 2.5) and bile salt (0.3%), and enhances the ability of the recombinant probiotics to remove reactive oxygen species (ROS), including hydrogen peroxide, superoxide anions, hydroxyl free radicals and DPPH free radicals.

Ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using Re-SILEX technology

Resumen de: CN121592655A

The invention discloses a method for screening an ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using a Re-SILEX technology, and belongs to the technical field of nucleic acid. The invention aims to solve the technical problem of how to effectively detect or target CD4 protein. In order to solve the technical problem, the invention provides a nucleic acid aptamer, the nucleic acid aptamer is at least one of nucleic acid aptamers with the name of CD4rzj-4a, CD4rzj-2a, CD4rzj-5a, CD4rzj-6a, CD4rzj-1b, CD4rzj-3a and CD4rzj-1a, and the nucleic acid aptamer CD4rzj-4a is a nucleic acid molecule with the nucleotide sequence of SEQ ID NO: 6. The aptamer provided by the invention has excellent specific binding force, and has important application potential in the field of CD4 detection or targeting.

METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

USE OF RIFAXIMIN IN SUBJECTS HAVING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用

Resumen de: CN121575078A

本发明涉及生物医学工程，公开了一种基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用。该筛选方法包括以下步骤：采用表面经仿生化处理的超表面等离子共振生物芯片，进行肠壁细胞培养或者小胶质细胞培养获得肠壁细胞贴壁或者小胶质细胞贴壁的芯片板，在细胞贴壁的芯片板内加入含化疗药物或脂多糖的培养基进行培养I，再除去培养基、加入待测治疗剂进行培养II得到培养液，检测所述培养液中肠壁细胞或者小胶质细胞的细胞修复效果；筛选获得对肠壁细胞和/或小胶质细胞具有修复作用的治疗剂。该筛选方法能够从多个待测治疗剂中高效、准确地筛选出兼具肠道调节与神经保护双重功效的治疗剂，且能够实现无标记、实时在线动态监测与探究治疗剂和细胞的相互作用情况。

Application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases

Nº publicación: CN121570596A 27/02/2026

Solicitante:

THE SECOND MILITARY MEDICAL UNIV
\u4E2D\u56FD\u4EBA\u6C11\u89E3\u653E\u519B\u6D77\u519B\u519B\u533B\u5927\u5B66

Resumen de: CN121570596A

The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.